Understand the source comparison
Best Peptides for NAFLD: Mechanism Comparison
GLP-1 Agonists (Semaglutide, Tirzepatide) Insulin sensitisation, reduced hepatic glucose output, slowed gastric emptying 30–40% hepatic fat reduction, 59% NASH resolution in NEJM trial 2.4mg weekly (semaglutide), 10–15mg weekly (tirzepatide) ~5–7 days; stable
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GLP-1 Agonists (Semaglutide, Tirzepatide)
- Insulin sensitisation, reduced hepatic glucose output, slowed gastric emptying
- 30–40% hepatic fat reduction, 59% NASH resolution in NEJM trial
- 2.4mg weekly (semaglutide), 10–15mg weekly (tirzepatide)
- ~5–7 days; stable 28 days refrigerated once reconstituted
- Strongest human trial evidence for NASH resolution. Direct hepatic effects beyond weight loss
- GH Secretagogues (MK 677, Hexarelin)
- Increased GH/IGF-1, enhanced mitochondrial biogenesis, visceral fat reduction
- Improved hepatocyte regeneration, reduced visceral adiposity in metabolic syndrome cohorts
- 10–25mg daily (MK 677), cycled dosing to prevent desensitisation
- 4–6 hours; stable 30 days refrigerated as reconstituted solution
- Promising for metabolic optimisation but limited liver-specific outcome data in humans
- Thymic Peptides (Thymalin)
- T-cell modulation, reduced pro-inflammatory cytokine release (IL-6, TNF-alpha)
- Dampened hepatic inflammation, potential reduction in stellate cell activation
- 5–10mg subcutaneous daily for 10 days, repeated every 2–3 months
- <2 hours; must be used within hours of reconstitution
- Mechanistically sound for NASH inflammatory component. Human liver data still emerging